Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma

摘要

BCMA-positive myeloma cells on 17 days before CAR-T cell therapy detected by flow cytometry. Measures of INF-γ, IL-6, and IL-10 after chimeric antigen receptor (CAR)-T BCMA cells infusion. Changes of temperature and white blood cells after CAR-T BCMA cells infusion (a is the time of BCMA CAR-T cells infusion and b is the time of stem cell infusion). BCMA-positive myeloma cells on 30 days after CAR-T cell therapy detected by flow cytometry. CAR-T cell frequency after BCMA CAR-T cells infusion. Changes of IgG and λ-IgLC before and after BCMA CAR-T cells infusion (The line a is the upper normal limit of IgG (1800 mg/dL) and the line b is the upper normal limit of λ-IgLC (2.42 g/L)). Changes of M spike and phlogocyte in bone marrow before and after BCMA CAR-T cells infusion